Abstract
To measure the magnetic resonance (MR) artefact produced by a percutaneous pulmonary valve stent and to evaluate the changes in volumetric and functional right ventricle (RV) parameters due to percutaneous pulmonary valve implantation (PPVI). A Melody valve was studied in vitro using clinical cardiac MR (CMR) sequences. In vivo, we analysed the CMR examinations obtained before and after PPVI of 27 consecutive patients. The echocardiography pressure gradient (PG) and catheter PG were measured. The Wilcoxon test was used for comparisons. In vitro, the least difference between artefact extent and actual valve size (0.1 mm) was obtained with a steady-state free precession (SSFP) sequence. In vivo, RV end-diastolic volume (ml/m(2)), end-systolic volume (ml/m(2)) and ejection fraction (%) were 79 ± 42, 43 ± 41 and 49 ± 13 before PPVI and 64 ± 21 (p = 0.054), 30 ± 14 (p = 0.021), and 54 ± 12 (p = 0.018) 6 months after PPVI, respectively. The PG and regurgitation fraction (RF) were 36 ± 15 mmHg and 14 ± 18 % before PPVI and 13 ± 15 mmHg (p < 0.001) and 2 ± 5 % (p = 0.013) after PPVI, respectively. No significant differences were found comparing the PG measured with CMR, echocardiography and catheter. We showed in vitro that the SSFP sequence produced the most accurate valve measurement. After PPVI, CMR showed a strong decrease of PG and RF with a significant improvement of RV function.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
